Pharmaceutical R&D spending and threats of price regulation

Journal of Financial and Quantitative Analysis

Volumn 45, Issue 1, 2010, Pages 239-264

  Golec, Joseph ^a   Hegde, Shantaram ^a   Vernon, John A ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b IL   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953547978     PISSN: 00221090     EISSN: 17566916     Source Type: Journal    
DOI: 10.1017/S0022109009990512     Document Type: Article

References (38)

1. Abbott, T. A. "Price Regulation in the Pharmaceutical Industry: Prescription or Placebo?" Journal of Health Economics, 14 (1995), 551-565.
2. Acemoglu, D., and J. Linn. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry." Quarterly Journal of Economics, 119 (2004), 1049-1090.
3. Brown, S. J., and J. B. Warner. "Measuring Security Price Performance." Journal of Financial Economics, 8 (1980), 205-258.
4. Bureau of Labor Statistics (BLS). http://www.bls.gov/cpi/home.htm#data Chan, L. K. C.; J. Lakonishok; and T. Sougiannis. "The Stock Market Valuation of Research and Development Expenditures." Journal of Finance, 56 (2001), 2431-2456.
5. Coulson, N. E., and B. C. Stuart. "Insurance Choice and the Demand for Prescription Drugs." Southern Economic Journal, 61 (1995), 1146-1157.
6. DiMasi, J. A.; R.W. Hansen; and H. G. Grabowski. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics, 22 (2003), 151-185.
7. Duggan, M., and F. M. Scott Morton. "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing." Quarterly Journal of Economics, 121 (2006), 1-30.
8. Durnev, A.; R. Morck; and B. Yeung. "Value-Enhancing Capital Budgeting and Firm-Specific Stock Return Variation." Journal of Finance, 59 (2004), 65-105.
9. Eberhart, A. C.;W. F. Maxwell; and A. R. Siddique. "An Examination of Long-Term Abnormal Stock Returns and Operating Performance following R&D Increases." Journal of Finance, 59 (2004), 623-650.
10. Ellison, S. F., andW. P. Mullin. "Gradual Incorporation of Information: Pharmaceutical Stocks and the Evolution of President Clinton's Health Care Reform." Journal of Law and Economics, 44 (2001), 89-129.
11. Ellison, S. F., and C. Wolfram. "Pharmaceutical Prices and Political Activity." Working Paper, Massachusetts Institute of Technology (2001).
12. Eurostat. http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/ home Finkelstein, A. "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry." Quarterly Journal of Economics, 119 (2004), 527-564.
13. Galai, D., and R. W. Masulis. "The Option Pricing Model and the Risk Factor of Stock." Journal of Financial Economics, 3 (1976), 53-81.
14. Garlappi, L. "Risk Premia and Preemption in R&D Ventures." Journal of Financial and Quantitative Analysis, 39 (2004), 843-872.
15. Giaccotto, C.; R. E. Santerre; and J. A. Vernon. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry." Journal of Law and Economics, 48 (2005), 195-214.
16. Grabowski, H. "The Determinants of Industrial Research and Development: A Study of Chemical, Drug, and Petroleum Industries." Journal of Political Economy, 76 (1968), 292-306.
17. Grabowski, H., and J. Vernon. "A New Look at the Returns and Risks to Pharmaceutical R&D." Management Science, 36 (1990), 804-821.
18. Guedj, I., and D. Scharfstein. "Organizational Scope and Investment: Evidence from Drug Development Strategies and Performance of Biopharmaceutical Firms." Working Paper, Massachusetts Institute of Technology (2004).
19. Hall, B. H. "The Financing of Research and Development." Oxford Review of Economic Policy, 18 (2002), 35-51.
20. Hall, B. H. "Exploring the Patent Explosion." Journal of Technology Transfer, 30 (2005), 35-48.
21. Hall, B. H.; A. Jaffe; and M. Trajtenberg. "Market Value and Patent Citations." RAND Journal of Economics, 36 (2005), 16-38.
22. Himmelberg, C. P., and B. C. Petersen. "R&D and Internal Finance: A Panel Study of Small Firms in High-Tech Industries." Review of Economics and Statistics, 76 (1994), 38-51.
23. Kaplan, S. N., and L. Zingales. "Do Investment-Cash Flow Sensitivities Provide Useful Measures of Financing Constraints?" Quarterly Journal of Economics, 112 (1997), 169-215.
24. Lamont, O.; C. Polk; and J. Saa-Requejo. "Financial Constraints and Stock Returns." Review of Financial Studies, 14 (2001), 529-554.
25. Lerner, J.; H. Shane; and A. Tsai. "Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances." Journal of Financial Economics, 67 (2003), 411-446.
26. Lichtenberg, F. R. "Public Policy and Innovation in the U.S. Pharmaceutical Industry." In Public Policy and the Economics of Entrepreneurship, D. Holtz-Eakin and H. S. Rosen, eds. Boston, MA: MIT Press (2004).
27. Manheimer, E., and D. Anderson. "Survey of Public Information about Ongoing Clinical Trials Funded by Industry: Evaluation of Completeness and Accessibility." British Medical Journal, 325 (2002), 528-531.
28. Mikkelson, W. H., and M. M. Partch. "Do Persistent Large Cash Reserves Hinder Performance?" Journal of Financial and Quantitative Analysis, 38 (2003), 275-294.
29. OECD. OECD Health Data 2003: A Comparative Analysis of 30 Countries. Paris, France: OECD Publishing (2003).
30. Pharmaceutical Researchers and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile. Washington, DC: PhRMA (1990-2000).
31. Scherer, F. M. "The Link between Gross Profitability and Pharmaceutical R&D Spending." Health Affairs, 20 (2001), 216-220.
32. Schwartz, E. S. "Patents and R&D as Real Options." Economic Notes, 33 (2004), 23-54.
33. Tessoriero, H. "Torrid Drug Price Increases Pause." The Wall Street Journal (December 6, 2004), A3.
34. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research, http://www.fda .gov/Drugs/InformationOnDrugs/default.htm (2010).
35. Vernon, J. A. "Drug Research and Price Controls." Regulation, 25 (2002/2003), 22-25.
36. Vernon, J. A. "Simulating the Impact of Price Regulation on R&D Innovation." Pharmaceutical Development and Regulation, 1 (2003), 55-65.
37. Vernon, J. A. "Examining the Link between Price Regulation and Pharmaceutical R&D Investment." Health Economics, 14 (2005), 1-16.
38. White, H. "A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity." Econometrica, 48 (1980), 817-838.